Literature DB >> 31288259

Overcoming barriers to hepatitis C elimination.

Manuel Mendizabal1,2, Cristina Alonso1,2, Marcelo O Silva1,2.   

Abstract

Keywords:  antiviral therapy; hepatitis C

Year:  2019        PMID： 31288259      PMCID： PMC6583574          DOI： 10.1136/flgastro-2018-101114

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  7 in total

1.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

2.  Access to care: Management of hepatitis C viral infection in remote locations.

Authors:  Sanjeev Arora; Karla Thornton; Andrea Bradford
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-07-23

Review 3.  Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS.

Authors:  Nathan Ford; Kasha Singh; Graham S Cooke; Edward J Mills; Tido von Schoen-Angerer; Adeeba Kamarulzaman; Philipp du Cros
Journal:  Clin Infect Dis       Date:  2012-03-19       Impact factor: 9.079

4.  EASL Recommendations on Treatment of Hepatitis C 2018.

Authors: 
Journal:  J Hepatol       Date:  2018-04-09       Impact factor: 25.083

5.  Facilitating treatment of HCV in primary care in regional Australia: closing the access gap.

Authors:  Lauren White; Ali Azzam; Lauren Burrage; Clare Orme; Barbara Kay; Sarah Higgins; Simone Kaye; Andrew Sloss; Jennifer Broom; Nicola Weston; Jonathan Mitchell; James O'Beirne
Journal:  Frontline Gastroenterol       Date:  2018-10-24

Review 6.  The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.

Authors:  Baligh R Yehia; Asher J Schranz; Craig A Umscheid; Vincent Lo Re
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

Review 7.  Where we are with point-of-care testing.

Authors:  A Johannessen
Journal:  J Viral Hepat       Date:  2015-04       Impact factor: 3.728
  7 in total
  5 in total

1.  Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing.

Authors:  Kozue Yamauchi; Mitsuaki Sato; Leona Osawa; Shuya Matsuda; Yasuyuki Komiyama; Natsuko Nakakuki; Hitomi Takada; Ryo Katoh; Masaru Muraoka; Yuichiro Suzuki; Akihisa Tatsumi; Mika Miura; Shinichi Takano; Fumitake Amemiya; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Taisuke Inoue; Shinya Maekawa; Nobuyuki Enomoto
Journal:  Hepatol Commun       Date:  2022-03-31

2.  An Investigation of the Side Effects, Patient Feedback, and Physiological Changes Associated with Direct-Acting Antiviral Therapy for Hepatitis C.

Authors:  Pin-Sheng Wu; Te-Sheng Chang; Sheng-Nan Lu; Hsiang-Jou Su; Shu-Zhi Chang; Chia-Wen Hsu; Mei-Yen Chen
Journal:  Int J Environ Res Public Health       Date:  2019-12-07       Impact factor: 3.390

3.  Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).

Authors:  Daniel O'Keefe; J Gunn; Kathleen Ryan; Filip Djordjevic; Phoebe Kerr; Judy Gold; Imogen Elsum; Chloe Layton; Kico Chan; Paul Dietze; Peter Higgs; Joseph Doyle; Mark A Stoové; Margaret Hellard; A E Pedrana
Journal:  BMJ Open       Date:  2022-01-04       Impact factor: 2.692

4.  Barriers to scaling up hepatitis C treatment in Malaysia: a qualitative study with key stakeholders.

Authors:  Huan-Keat Chan; Mohamed Azmi Hassali; Noor Syahireen Mohammed; Azlina Azlan; Muhammad Radzi Abu Hassan
Journal:  BMC Public Health       Date:  2022-02-21       Impact factor: 3.295

Review 5.  Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.

Authors:  Chung-Feng Huang; Ming-Lung Yu
Journal:  Clin Mol Hepatol       Date:  2020-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.